Malissa Paxton
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 323 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,768, 2.1 times the $860 reported in 2021.
Across 323 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$928
- AstraZeneca$423
- Pfizer$344
- Lilly USA, LLC$292
- GSK$244
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,317100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 58 | $1,086 |
| AbbVie | 75 | $928 |
| AstraZeneca | 21 | $423 |
| Pfizer | 22 | $344 |
| Lilly USA, LLC | 19 | $292 |
| GSK | 14 | $244 |
| Amgen(2 entities) | 13 | $238 |
| Astellas Pharma US Inc | 12 | $209 |
| Dexcom, Inc. | 5 | $188 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $140 |
| Bayer | 8 | $126 |
| Johnson & Johnson | 7 | $107 |
| Amarin Pharma, Inc. | 6 | $106 |
| Merck | 7 | $101 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $97 |
| Sanofi-aventis U.S. LLC | 6 | $92 |
| Exact Sciences | 5 | $72 |
| Abbott | 4 | $70 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $60 |
| Insulet Corporation | 3 | $47 |
| Aimmune Therapeutics, Inc. | 2 | $45 |
| Corcept Therapeutics | 2 | $43 |
| Medtronic | 2 | $41 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Boehringer Ingelheim | 2 | $30 |
| Daiichi Sankyo Inc. | 2 | $27 |
| Biohaven Pharmaceuticals, Inc. | 2 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $13 |
| Genentech USA, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$231
- BREZTRI$126
- FARXIGA$126
- AIRSUPRA$126
- DEXCOM G7 GSS (161)$109
- DEXCOM STELO GLUCOSE BIOSENSOR$109
- ZAVZPRET$103
How this compares
$5,317 in reported general payments places this provider in the 85th percentile of 205 medical providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 34 | $50,263 |
| FarxigaDapagliflozin Propanediol | 13 | $9,845 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,576 |
| XareltoRivaroxaban | 12 | $6,684 |
| Spiriva HandihalerTiotropium Bromide | 12 | $6,330 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $4,965 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,860 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 102 | $2,166 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 73 | $1,841 |
| SynthroidLevothyroxine Sodium | 21 | $1,789 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 20 | $1,367 |
| Doxycycline Hyclate | 25 | $1,309 |
| Metoprolol Succinate | 65 | $1,148 |
| Duloxetine Hcl | 66 | $1,146 |
| Atorvastatin Calcium | 147 | $877 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,086 | $50,26334 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $423 | $22,28140 claims |
| Johnson & JohnsonXarelto | $107 | $6,68412 claims |
| GSKBreo Ellipta | $244 | $4,96513 claims |
| AbbVieSynthroid | $928 | $1,78921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 205 medical providers in Kansas.
Other medical in Derby
- Edwin PriceDerby$2K
- Linly StevensOverland Park$111K
- Shana ArnholdShawnee$82K
- Richard AllenbachWichita$70K
- Laura LudlowTopeka$61K
- Anita KishOlathe$58K
- Kathryn WelchWichita$32K
- Courtney SteneOverland Park$22K
- Janella DewittOverland Park$19K
- Walter DeanMission$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.